ArticleFrontiers in surgery2026
Weight-based, anti-Xa guided enoxaparin after spine trauma surgery: target attainment and safety in a retrospective cohort.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Patients undergoing surgery for traumatic spine injuries have a high risk of venous thromboembolism (VTE). Standard fixed or weight-based enoxaparin regimens may leave some patients below prophylactic anti-factor Xa (anti-Xa) target ranges. Whether anti-Xa-guided enoxaparin dose adjustment can be implemented while maintaining acceptable observed bleeding outcomes has not been studied specifically in postoperative spine trauma patients. This study evaluates anti-Xa target attainment, symptomatic VTE, and safety outcomes after anti-Xa-guided enoxaparin titration. Methods: We performed a retrospective cohort study of adults (≥18 years old) who underwent operative treatment for traumatic spine injuries at a Level I trauma center. All patients received weight-based enoxaparin starting 24 h postoperatively (30 mg every 12 h if <90 kg, 40 mg every 12 h if ≥90 kg) plus mechanical VTE prophylaxis and early mobilization. In the anti-Xa cohort, levels were obtained 4 h after the third dose (target 0.2-0.4 IU/mL) and doses were adjusted by 10 mg if outside this range. A comparison cohort received the same initial dosing without anti-Xa monitoring. The primary outcome was symptomatic postoperative VTE. Secondary outcomes included bleeding requiring transfusion, spinal epidural hematoma, hospital length of stay, and ambulation at discharge. Results: A total of 354 patients were included (170 anti-Xa; 184 fixed dose). Symptomatic VTE was rare and similar between groups (1.1% vs. 1.6%). No postoperative epidural hematomas occurred. In the anti-Xa cohort, 28% required dose escalation and 7% required more than one adjustment. In exploratory adjusted analyses, bleeding requiring transfusion and length of stay did not differ between groups. Conclusions: Weight-based enoxaparin with anti-Xa-guided titration was feasible after spine trauma surgery and identified a substantial subset of patients below the prespecified prophylactic anti-Xa target range. Protocol-based dose escalation was not associated with an observed increase in bleeding requiring transfusion, and no postoperative epidural hematomas occurred. Larger prospective studies are needed to determine whether improved anti-Xa target attainment translates into lower VTE rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.